| 18.33 0.83 (4.74%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 24.49  |
1-year : | 27.59 |
| Resists | First : | 20.97 |
Second : | 23.62 |
| Pivot price | 18.24 |
|||
| Supports | First : | 16.68 |
Second : | 13.87 |
| MAs | MA(5) : | 17.99 |
MA(20) : | 18.63 |
| MA(100) : | 17.91 |
MA(250) : | 13.07 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 22.8 |
D(3) : | 20.7 |
| RSI | RSI(14): 47.5 |
|||
| 52-week | High : | 23.62 | Low : | 5 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PRE ] has closed below upper band by 47.1%. Bollinger Bands are 43% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 18.35 - 18.46 | 18.46 - 18.57 |
| Low: | 16.44 - 16.56 | 16.56 - 16.67 |
| Close: | 18.13 - 18.32 | 18.32 - 18.51 |
Prenetics Global Limited, an investment holding company, operates as a diagnostics and genetic testing company. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring system that allows users to take COVID-19 tests at point-of-care or at home utilizing the nucleic acid amplification test. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; Circle Medical, a diagnostic testing product; and Circle One and F1x/Fem. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.
Fri, 24 Apr 2026
Prenetics Global: Quarterly Subscription Focus Could Bring In Profitability (NASDAQ:PRE) - Seeking Alpha
Wed, 22 Apr 2026
Genetel and Michael Yang report 3.3% stake in Prenetics Global (PRE) - Stock Titan
Sat, 18 Apr 2026
Prenetics Global: On Course To Hit Profitability Amid Globalization Drive (NASDAQ:PRE) - Seeking Alpha
Fri, 10 Apr 2026
PRE Options Volatility — NASDAQ:PRE - TradingView
Fri, 10 Apr 2026
PRE Options Chain — NASDAQ:PRE - TradingView
Thu, 02 Apr 2026
Giannis Antetokounmpo joins Prenetics (NASDAQ: PRE) as IM8 partner and shareholder - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 15 (M) |
| Shares Float | 12 (M) |
| Held by Insiders | 18.1 (%) |
| Held by Institutions | 13.9 (%) |
| Shares Short | 573 (K) |
| Shares Short P.Month | 476 (K) |
| EPS | -3.79 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.89 |
| Profit Margin | -63.2 % |
| Operating Margin | -33.3 % |
| Return on Assets (ttm) | -11.1 % |
| Return on Equity (ttm) | -31.8 % |
| Qtrly Rev. Growth | 248.6 % |
| Gross Profit (p.s.) | 3.2 |
| Sales Per Share | 6.04 |
| EBITDA (p.s.) | -2.16 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -23 (M) |
| Levered Free Cash Flow | -61 (M) |
| PE Ratio | -4.84 |
| PEG Ratio | 0 |
| Price to Book value | 1.68 |
| Price to Sales | 3.03 |
| Price to Cash Flow | -12.24 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|